human tissue kit Manufacturers, Suppliers, Factory
Our rewards are reduce selling prices,dynamic revenue team,specialized QC,sturdy factories,superior quality services for human-tissue-kit, oct compound kit, lung microsomes kit, PBMC isolation kit, rat PBMC kit. Now now we have recognized steady and long organization relationships with customers from North America, Western Europe, Africa, South America, extra than 60 countries and regions. Our company absorbs new ideas, strict quality control, a full range of service tracking, and adhere to make high-quality solutions. Our business aims to "honest and trustworthy, favorable price, customer first", so we won the trust of the majority of customers! If you are interested in our items and services, please do not hesitate to contact us! Monkey Tissue kit, monkey serum kit, feline PBMC kit, cat PBMC kit.
The 63rd SOT ended perfectly, and the excitement of IPHASE-US never ends!
The 63rd Annual Meeting and Exposition of the American Society of Toxicology was successfully held from March 10-14, 2024, in
Revolutionary Therapeutics: Antibody-Oligonucleotide Conjugates (AOCs) – The Future of Precision Medicine
In the rapidly evolving world of biopharmaceuticals, Antibody-Oligonucleotide Conjugates
IPHASE, as a leader in biological reagents for in vitro research of innovative medicines, continues to introduce high-end research reagents in multiple fields and types based on years of research and development experience.
Introduction to mRNA drugs Messenger RNA (mRNA) is a sequence of nucleotides that encodes a protein, and in the cytoplasm is able to use organelles to express the encoded protein. mRNA drugs are chemi
PDC in vitro ADME research model PDC takes into account the characteristics of both large and small molecules. Therefore, in vitro ADME research on it needs to take into account homing peptides, linke
Recently, IPHASE, in conjunction with the Perelman School of Medicine at the University of Pennsylvania, co-authored an article in the journal Antibody Therapeutics (IF=4.56) titled "Development of a